Etorza P
Etorza P Uses, Dosage, Side Effects, Food Interaction and all others data.
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities. Etoricoxib is a potent, orally active & highly selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 is primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Etoricoxib decreases these clinical signs and symptoms effectively with decreased GI toxicity. Moreover it has no effect on platelet function.
Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).
Trade Name | Etorza P |
Generic | Etoricoxib + Paracetamol / Acetaminophen |
Weight | 60mg |
Type | Tablet |
Therapeutic Class | |
Manufacturer | Zenon Healthcare Ltd |
Available Country | India |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Etoricoxib is used for relief of pain and inflammation in-
- Osteoarthritis
- Rheumatoid arthritis
- Other chronic musculoskeletal disorders
- Acute gout
- Dysmenorrhoea
- Following dental surgery
Etorza P is also used to associated treatment for these conditions: Ankylosing Spondylitis (AS), Gouty Arthritis, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain
How Etorza P works
Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.
Dosage
Etorza P dosage
The recommended dose for adult and patient over 16 years:
- Acute pain: 120 mg once daily. Etoricoxib 120 mg should be used only for acute symptomatic period, limited to a maximum of 8 days treatment.
- Chronic musculoskeletal pain: 60 mg once daily.
- Osteoarthritis: 30 mg once daily, increased if necessary to 60 mg once daily.
- Rheumatoid arthritis and ankylosing spondylitis: 90 mg once daily.
- Acute gout: 120 mg once daily for max. 8 days. Max. 60 mg daily in mild hepatic impairment; max. 60 mg on alternate days or 30 mg once daily in moderate hepatic impairment.
Side Effects
Dry mouth, taste disturbance, mouth ulcer, flatulence, constipation, appetite and weight changes, chest pain , fatigue, paraesthesia, influenza like syndrome, myalgia etc. may occur.
Toxicity
This reduced activity is the cause of reduced gastrointestinal toxicity, as demonstrated in several large clinical trials performed with different COXIB (see below links on NEJM and The Lancet). Some clinical trials and meta-analysis showed that treatment with COXIB lead to increased incidence of cardiovascular adverse events compared to placebo
Precaution
A patient with decreased liver & kidney function, dehydration, hypertension, heart failure, GI perforation & patients over 65 years of age. Use in Pregnancy and Lactation As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.
Interaction
Oral anticoagulants, diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin and Tacrolimus, Lithium, Methotrexate, oral contraceptives, Prednisone/Prednisolone, Digoxin, drugs metabolized by sulfotransferases (Ethinyl Estradiol), drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin, and Antacids have interaction with Etoricoxib.
Elimination Route
Bioavailability is 100% following oral administration.
Half Life
22 hours
Pregnancy & Breastfeeding use
As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only ifthe potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.
Contraindication
It is contraindicated in patients with hypersensitivity to Etoricoxib or any component of this product, congestive heart failure, patients with inflammatory bowel disease, severe hepatic dysfunction.
Acute Overdose
Symptoms: GI and cardiorenal events.
Management: Symptomatic and supportive treatment. Remove unabsorbed material from the GI tract.
Storage Condition
Store at a cool & dry place protected from light & moisture. Keep out of reach of children.
Innovators Monograph
You find simplified version here Etorza P